FDA approves first immunotherapy for recurrent respiratory papillomatosis

Sarepta advances siRNA collaboration and sale of arrowhead equity investment

Sarepta has also entered into an agreement with Arrowhead to transfer 2,660,989 shares of Arrowhead common stock in satisfaction of $50 million of the company’s previously announced $100 million milestone payment obligation

BioAge Labs doses first patient in BGE-102 phase 1 trial

The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants

AN2 Therapeutics begins first-in-human trial of oral AN2-502998 for chagas disease

Phase 1 dosing is expected to finish by the end of 2025

AAVantgarde Bio receives FDA fast track designation for AAVB-039 in stargardt disease

The therapy delivers the full-length ABCA4 protein and has the potential to benefit all patients with ABCA4 mutations

Asian Institute of Nephrology & Urology expands hospital in Banjara Hills, Hyderabad

AINU is set to accelerate its expansion footprint, enhance operational capabilities

Athena Diagnostics enhances Ataxia testing with long-read gene sequencing

Athena is also exploring the use of this technology for expanded carrier screening

Sanofi’s GPRC5D monoclonal antibody earns ODD in US for multiple myeloma

Beta-HPV can directly cause skin cancer in immunocompromised people

cSCC is one of the most common cancers in the U.S. and globally

NIH develops AI agent to improve accuracy of gene set analysis

The system, called GeneAgent, cross-checks its own initial predictions for accuracy against information from established, expert-curated databases